ClinConnect ClinConnect Logo
Search / Trial NCT06309238

Intensive Weight Loss Intervention Versus Bariatric Surgery for Adults With Severe and Complex Obesity: the LightBAR Randomised Trial

Launched by CARSTEN DIRKSEN · Mar 6, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

ClinConnect Summary

The LightBAR trial is studying two different ways to help adults with severe obesity lose weight: a non-surgical program that includes meal replacements, behavioral support, and weight-loss medications, versus bariatric surgery, which is a surgical option for weight loss. The goal is to understand which method works better and what the benefits and risks are for people who qualify for bariatric surgery. By comparing these two approaches, the results may help shape future treatments for individuals struggling with obesity.

To participate in this trial, you need to be between 18 and 60 years old and eligible for bariatric surgery based on specific health criteria. This may include having a high body mass index (BMI) and related health issues like diabetes or high blood pressure. Participants will be invited to join the study and can expect to either follow the intensive weight loss program or undergo surgery, with regular support and monitoring throughout the process. It's important to know that certain health conditions or previous surgeries may prevent someone from taking part in the trial, so a thorough screening will be done to ensure safety and suitability.

Gender

ALL

Eligibility criteria

  • Please note that participants need to be invited in order to take part in the trial.
  • Inclusion Criteria:
  • Aged 18 to 60 years (inclusive) at time of screening.
  • * Eligible for and willing to undergo bariatric surgery, i.e., fulfilment of criteria for bariatric surgery from the respective national health authorities:
  • DK: BMI ≥ 35 kg/m2 with one or more of the following: T2D, severe hypertension, sleep apnoea requiring treatment, symptomatic arthrosis in lower extremities, female infertility related to overweight, or BMI\>40 kg/m2 with other strong medical reasons for weight loss (28). Prior to surgery, an 8% weight loss is required as well as smoking cessation.
  • UK: BMI of 35 kg/m2 to 40 kg/m2 and other significant disease (e.g., type 2 diabetes or high blood pressure), or BMI ≥40 kg/m2. Has been or is willing to receive intensive management in a specialist tier 3 obesity service (29).
  • Fit for anaesthesia and surgery.
  • Informed consent.
  • Exclusion Criteria:
  • Prior bariatric or hiatal surgery, not including intragastric balloons or duodenal-jejunal bypass sleeve (Endobarrier™ or similar) if the device has been removed \>1 year before screening.
  • Use of any WLM (including liraglutide and semaglutide for diabetes) within last 3 months.
  • Conditions that contraindicate or complicate total diet replacement (including type 1 diabetes or other diabetes requiring basal bolus insulin therapy or insulin pump therapy (for Denmark) and any diabetes requiring insulin therapy (for UK), phenylketonuria, or other conditions requiring strict adherence to special diets).
  • Conditions that contraindicate or complicate treatment with GLP-1 receptor analogues (including history of pancreatitis or known allergies).
  • Conditions that contraindicate or complicate bariatric surgery (GI motility disorders, large abdominal wall hernia, large hiatus hernia (\>5cm), Crohn's disease, liver cirrhosis, or other conditions preventing laparoscopic bariatric surgery e.g. multiple previous abdominal surgery).
  • Conditions that contraindicate or complicate study adherence and bariatric surgery (mental disorder, unstable psychiatric disease, recent history of alcohol/medication abuse, cancer treatment within 5 years).
  • Pregnant or planning pregnancy in the next two years or currently breast feeding.
  • Not achieving a 5% weight loss within 12 weeks prior to randomisation.
  • People taking part in other research involving multidisciplinary obesity treatment that would compromise their participation in this trial.
  • Another member of the household enrolled in the trial.
  • Diagnosis of or treatment for severe eating disorder within the last 6 months.

About Carsten Dirksen

Carsten Dirksen is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a focus on enhancing patient outcomes, Dirksen oversees a range of clinical studies aimed at evaluating novel therapeutics and interventions across various therapeutic areas. His expertise in trial design, regulatory compliance, and data integrity ensures that each study is conducted with the highest standards of scientific rigor and ethical responsibility. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, Carsten Dirksen plays a pivotal role in translating scientific discoveries into effective treatments for patients.

Locations

Southampton, , United Kingdom

Truro, Cornwall, United Kingdom

Viborg, , Denmark

Aarhus, , Denmark

Esbjerg, , Denmark

Hvidovre, , Denmark

Køge, , Denmark

Bristol, , United Kingdom

Taunton, , United Kingdom

Cosham, Portsmouth, United Kingdom

Chichester, Sussex, United Kingdom

Patients applied

0 patients applied

Trial Officials

Carsten Dirksen, Ass Professor

Study Chair

Department of Medicine, Copenhagen University Hospital - Amager and Hvidovre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported